



AN ISO 9001 & A WHO GMP CERTIFIED COMPANY



To,

Date: 14.08.2021

1. BSE Limited, P.J. Towers, Dalal Street, Mumbai - 400001	2. National Stock Exchange of India Limited Bandra - Kurla Complex, Bandra (East) Mumbai 400051
--	---

Dear Sir/Madam,

Sub: Outcome of Board meeting held on 14.08.2021

Ref: Our Company's letter dated 02.08.2021

With reference to the subject cited, this is to inform the Exchange that at the meeting of the Board of Directors of Ortin Laboratories Limited held on Saturday, 14.08.2021 at 4:00 p.m. at the registered office of the company, the following were considered and approved:

1. Un-Audited financial results for the quarter ended 30.06.2021. **(Enclosed)**
2. Limited Review Report as per Regulation 33 of SEBI (LO&DR) Regulations, 2015 for the quarter ended 30.06.2021. **(Enclosed)**
3. Notice of 34th Annual General Meeting of the Members of the Company to be held on Thursday 30th of September, 2021 at 11:00 a.m. through video conferencing/other audio visual means.

The meeting concluded at 5:15 P.M.

This is for the information and records of the Exchange, please.

Thanking you.

Yours sincerely,
For Ortin laboratories Limited


S. Murali Krishna Murthy
Managing Director
DIN: 00540632



Encl: as above



Statement of Un-Audited Financial Results for the Quarter ended 30.06.2021

(Amount in Lakhs)

Particulars	Quarter Ended		For the Quarter ended 30.06.2020	Year Ended	
	For the Quarter ended 30.06.2021	For the Quarter ended 31.03.2021		For the Year ended 31.03.2021	For the Year ended 31.03.2020
	Un-Audited	Audited	Un-Audited	Audited	Audited
I Revenue From Operations	198.44	175.73	7,872.15	816.74	19,739.10
II Other Income	0.04	5.01	1.67	5.01	18.81
III Total Revenue (I+II)	198.48	180.73	7,873.81	821.75	19,757.91
IV Expenses					
(a) Cost of Materials consumed	116.39	58.94	7,733.28	407.82	16,514.98
(b) Purchase of stock-in-trade	-	-	-	-	-
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(8.25)	(52.69)	(991.10)	(12.80)	(1,052.79)
(d) Employee benefits expense	22.63	43.42	127.65	105.22	535.69
(e) Finance Cost	18.00	19.36	69.57	87.35	320.84
(f) Depreciation and amortisation expense	6.75	7.20	51.08	28.54	195.50
(h) Other expenses	31.21	104.95	847.66	191.98	3,171.83
Total Expenses	186.72	181.18	7,838.14	808.11	19,686.05
V Profit/ (Loss) before Exceptional Items and tax (III-IV)	11.76	(0.45)	35.68	13.65	71.85
VI Exceptional Items	-	-	-	-	-
VII Profit / (Loss) from before tax (V-VI)	11.76	(0.45)	35.68	13.65	71.85
VIII Tax Expense:					
Current Tax	3.06	5.70	10.72	5.70	22.25
Deferred Tax	(0.41)	(86.60)	7.60	(86.60)	22.68
Taxes of Earlier Years	-	-	-	-	83.32
IX Profit/ (Loss) for the period from continuing operations (IX-X)	9.11	80.45	17.36	94.55	(56.40)
X Profit/ (Loss) from discontinuing operations	-	-	-	-	-
XI Tax Expense of discontinuing operations	-	-	-	-	-
XII Profit/ (Loss) from discontinuing operations after tax	-	-	-	-	-
XIII Profit/(loss) for the Period (IX+XII)	9.11	80.45	17.36	94.55	(56.40)
XIV Other Comprehensive Income					
(i) Items that will not be recycled to profit or loss	-	-	-	-	(95.42)
A. (ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	24.02
(i) Items that may be reclassified to profit or loss	-	-	-	-	-
B. (ii) Income tax on items that may be reclassified to profit or loss	-	-	-	-	-
Total other Comprehensive Income	-	-	-	-	(71.41)
XV Total Comprehensive Income for the period (XIII+XIV)	9.11	80.45	17.36	94.55	(127.81)
XVI Earnings Per Equity Share of face value of Rs.10/- each (for Continuing operations):					
1) Basic	0.11	0.99	0.10	1.16	(0.33)
2) Diluted	0.11	0.99	0.10	1.16	(0.33)
XVII Earnings Per Equity Share of face value of Rs.10/- each (for Discontinuing operations):					
1) Basic	-	-	-	-	-
2) Diluted	-	-	-	-	-
XVIII Earnings Per Equity Share of face value of Rs.10/- each (for Continued and Discontinuing operations):					
1) Basic	0.11	0.99	0.10	1.16	(0.33)
2) Diluted	0.11	0.99	0.10	1.16	(0.33)
XIX Paid-up equity share capital (Face Value of Rs. 10/- per share)	813.14	813.14	1,694.04	813.14	1,694.04
XX Other Equity	-	-	-	322.41	687.55

NOTES:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 14.08.2021 in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The company adopted the Indian Accounting standards (Ind AS) and accordingly these results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS- 34 "Interim Financial Reporting" prescribed under Section 133 of Companies Act, 2013 read with the relevant rules issued thereunder and other accounting pronouncements generally accepted in India. The Ind-AS Compliant Financial results for the corresponding quarter 30.06.2021 have been stated in terms of SEBI Circular dated July, 05, 2016.
- The financial results are also available on the website of the Company www.ortinlabsindia.com
- As per the Orders dated 24.12.2020 of The Hon'ble NCLT, Hyderabad bench, Unit II of Ortin Laboratories Limited (API Intermediates) was demerged/hived off with Vineet Laboratories Limited w.e.f 01.04.2020. Accordingly, the unaudited financial results of the quarter ended 30.06.2021 are considered for the unit-I only and the financials of Unit-II which is demerged into Vineet Laboratories Limited is not included in the quarter ended 30.06.2021. The financial data for the quarter ended 30.06.2020 and year ended 31.03.2020 contains the financials for both Unit-I and unit-II
- Figures of the corresponding previous periods are not comparable as the Unit II of the company has been demerged and all assets, liabilities, income and expenses relating to Unit II has been transferred to demerged entity.
- The Company is operating only in one segment i.e., manufacturing and trading of drug formulations, therefore segment reporting as per Ind AS -108 is not applicable.
- Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.

For ORTIN LABORATORIES LIMITED
S.MURALI KRISHNA MURTHY

MANAGING DIRECTOR
(DIN: 00540632)

Place: Hyderabad
Date :14.08.2021



Independent Auditor's Review Report on Quarterly and Year to Date Unaudited Financial Results of Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To

The Board of Directors of
M/s ORTIN LABORATORIES LIMITED

We have reviewed the accompanying statement of unaudited financial results of **M/s ORTIN LABORATORIES LIMITED** ('The Company') for the quarter ended 30th June, 2021. This statement is the responsibility of the company's management and has been approved by the board of directors. Our responsibility is to issue a report on these financial statements based on our review

We conducted our review of the Statement in accordance with the Standards on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the entity' issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free from material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian accounting standards specified under section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting principles and policies has not disclosed the information required to be disclosed in terms of the regulation 33 of the SEBI (Listing Obligations and disclosure requirements) regulations, 2015 including the manner in which it is to be disclosed or that it contains any material misstatements..

For Sathuluri & Co
Chartered Accountants
Firm Reg No.006383S

(S.S.Prakash)
Partner
Membership No.202710

UDIN : 21202710AAAADV7547

Place: Hyderabad
Date: 14/08/2021